Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 64

1.

Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials.

Liu E, Schmidt ME, Margolin R, Sperling R, Koeppe R, Mason NS, Klunk WE, Mathis CA, Salloway S, Fox NC, Hill DL, Les AS, Collins P, Gregg KM, Di J, Lu Y, Tudor IC, Wyman BT, Booth K, Broome S, Yuen E, Grundman M, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators.

Neurology. 2015 Aug 25;85(8):692-700. doi: 10.1212/WNL.0000000000001877. Epub 2015 Jul 24.

2.

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators.

N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839.

3.

Thyrotropin-releasing hormone can relieve cancer-related fatigue: hypothesis and preliminary observations.

Kamath J, Yarbrough GG, Prange AJ Jr, Winokur A.

J Int Med Res. 2009 Jul-Aug;37(4):1152-7.

PMID:
19761698
4.

The thyrotropin-releasing hormone (TRH)-immune system homeostatic hypothesis.

Kamath J, Yarbrough GG, Prange AJ Jr, Winokur A.

Pharmacol Ther. 2009 Jan;121(1):20-8. doi: 10.1016/j.pharmthera.2008.09.004. Epub 2008 Oct 21. Review.

PMID:
19000920
5.

Allelic variance between GRM6 mutants, Grm6nob3 and Grm6nob4 results in differences in retinal ganglion cell visual responses.

Maddox DM, Vessey KA, Yarbrough GL, Invergo BM, Cantrell DR, Inayat S, Balannik V, Hicks WL, Hawes NL, Byers S, Smith RS, Hurd R, Howell D, Gregg RG, Chang B, Naggert JK, Troy JB, Pinto LH, Nishina PM, McCall MA.

J Physiol. 2008 Sep 15;586(18):4409-24. doi: 10.1113/jphysiol.2008.157289. Epub 2008 Aug 7.

6.

No somatic mutations detected in the Mad2 gene in 658 human tumors.

Ruddy DA, Gorbatcheva B, Yarbrough G, Schlegel R, Monahan JE.

Mutat Res. 2008 May 10;641(1-2):61-3. doi: 10.1016/j.mrfmmm.2008.02.008. Epub 2008 Mar 2. No abstract available.

PMID:
18423499
7.

Thyrotropin-releasing hormone (TRH) in the neuroaxis: therapeutic effects reflect physiological functions and molecular actions.

Yarbrough GG, Kamath J, Winokur A, Prange AJ Jr.

Med Hypotheses. 2007;69(6):1249-56. Epub 2007 Jun 5.

PMID:
17553626
8.

Stimulation via a subretinally placed prosthetic elicits central activity and induces a trophic effect on visual responses.

DeMarco PJ Jr, Yarbrough GL, Yee CW, McLean GY, Sagdullaev BT, Ball SL, McCall MA.

Invest Ophthalmol Vis Sci. 2007 Feb;48(2):916-26.

PMID:
17251495
9.

Ethical and legal issues in nutrition support of the geriatric patient: the can, should, and must of nutrition support.

Barrocas A, Yarbrough G, Becnel PA 3rd, Nelson JE.

Nutr Clin Pract. 2003 Feb;18(1):37-47. No abstract available.

PMID:
16215019
10.

The neuroprotective effects of BNG-1: a new formulation of traditional Chinese medicines for stroke.

Cheng FC, Chen WL, Wei JW, Huang KS, Yarbrough GG.

Am J Chin Med. 2005;33(1):61-71.

PMID:
15844834
11.

Judging egocentric distance on the ground: occlusion and surface integration.

He ZJ, Wu B, Ooi TL, Yarbrough G, Wu J.

Perception. 2004;33(7):789-806.

PMID:
15460507
12.

Fundamental molecular mechanism of the CNS effects of TRH.

Yarbrough GG.

Trends Pharmacol Sci. 2003 Dec;24(12):617-8. No abstract available.

PMID:
14654301
13.

The thyrotropin-releasing hormone (TRH) hypothesis of homeostatic regulation: implications for TRH-based therapeutics.

Gary KA, Sevarino KA, Yarbrough GG, Prange AJ Jr, Winokur A.

J Pharmacol Exp Ther. 2003 May;305(2):410-6. Epub 2003 Feb 20. Review.

14.

Molecular approaches to receptors as targets for drug discovery.

Herz JM, Thomsen WJ, Yarbrough GG.

J Recept Signal Transduct Res. 1997 Sep;17(5):671-776. Review.

PMID:
9292776
15.

Screening microbial metabolites for new drugs--theoretical and practical issues.

Yarbrough GG, Taylor DP, Rowlands RT, Crawford MS, Lasure LL.

J Antibiot (Tokyo). 1993 Apr;46(4):535-44. Review. No abstract available.

16.

The amateur Radio Emergency Service (ARES) and the National Disaster Medical System (NDMS).

Niemtzow RC, Yarbrough G, Harwood KL, Jacobs JL, Burkett S, Greaves WW, Reutershan TP, Rebuck HI, Posner S, Clark W, et al.

Mil Med. 1993 Apr;158(4):259-63.

PMID:
8479634
17.

Cell receptors as drugs. Ligand binding domains of receptors as drugs: a potential new class of therapeutic agents.

Yarbrough GG, Taylor DP.

J R Coll Physicians Lond. 1991 Oct;25(4):309-11. Review.

PMID:
1960687
18.

Contact immunotherapy of resistant warts.

Naylor MF, Neldner KH, Yarbrough GK, Rosio TJ, Iriondo M, Yeary J.

J Am Acad Dermatol. 1988 Oct;19(4):679-83. Review.

PMID:
3053802
19.

Diabetic patient with crusted plaques. Crusted (Norwegian) scabies.

Yarbrough GK, Iriondo M.

Arch Dermatol. 1987 Jun;123(6):811, 814. No abstract available.

PMID:
3579360
20.

Prospective strategies for cholinergic interventions in Alzheimer's disease.

Pomara N, Bagne CA, Stanley M, Yarbrough GG.

Prog Neuropsychopharmacol Biol Psychiatry. 1986;10(3-5):553-69. Review.

PMID:
3541050

Supplemental Content

Loading ...
Support Center